Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer

  • Solinas, Cinzia
  • Llop-Guevara, Alba
  • Pellegrino, Benedetta
  • Pimentel, Isabel
  • Villacampa Javierre, Guillermo
  • Torres-Esquius, Sara
  • Simonetti, Sara
  • Saura Manich, Cristina
  • Balmaña, Judith
  • Serra, Violeta
Homologous recombination deficiency; Survival; Breast cancer, Deficiencia de recombinación homóloga; Supervivencia; Cáncer de mama, Deficiència de recombinació homòloga; Supervivència; Càncer de mama, Advances in breast cancer (BC) therapy are limited by the absence of well-established biomarkers for DNA-damage targeted treatments. We evaluated the predictive and prognostic value of homologous recombination repair (HRR) deficiency (HRD) by RAD51 nuclear foci and stromal tumour-infiltrating lymphocytes (TILs) in early-stage BC patients with suspected germline susceptibility. Among 291 patients, HRD by RAD51 was found in 78.4% of tumours, and 69.8% had low TILs (<30%). In 178 patients treated with neoadjuvant chemotherapy, pathologic complete response (pCR) was higher in those with HRD vs HRR-proficient (HRP) tumours (52.3% vs 36.4%); RAD51 remained independently associated with pCR (p = 0.03). Overall survival (OS) favoured HRD, with 5-year OS of 89.2% vs 82.8% in HRP (p = 0.009), with stronger evidence in triple-negative TILs-low disease (p = 0.005). These findings support RAD51-based HRD assessment as a predictive and prognostic biomarker that may guide treatment decisions in early-stage BC., We acknowledge C. Belli, F. Pedretti, A. Herencia-Ropero, M. Guzmán and O. Rodríguez for technical support. VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, the CERCA program from the Generalitat de Catalunya and patients and families for their support on this research. This study was also supported by the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). This work received funds from Asociación Española contra el cancer [AECC, LABAE16020PORTT], Institutode Salud Carlos III [PI23/00506] and the Catalan Agency AGAUR-FEDER [2021 SGR 01510 to V.S and 2022 SGR 01112 to J.B), AL-G and C.C. were supported by AECC [INVES20095LLOP, AIOC15152806CRUZ].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer

  • Solinas, Cinzia
  • Llop-Guevara, Alba
  • Pellegrino, Benedetta
  • Pimentel, Isabel
  • Villacampa Javierre, Guillermo
  • Torres-Esquius, Sara
  • Simonetti, Sara
  • Saura Manich, Cristina
  • Balmaña, Judith
  • Serra, Violeta
Homologous recombination deficiency; Survival; Breast cancer, Deficiencia de recombinación homóloga; Supervivencia; Cáncer de mama, Deficiència de recombinació homòloga; Supervivència; Càncer de mama, Advances in breast cancer (BC) therapy are limited by the absence of well-established biomarkers for DNA-damage targeted treatments. We evaluated the predictive and prognostic value of homologous recombination repair (HRR) deficiency (HRD) by RAD51 nuclear foci and stromal tumour-infiltrating lymphocytes (TILs) in early-stage BC patients with suspected germline susceptibility. Among 291 patients, HRD by RAD51 was found in 78.4% of tumours, and 69.8% had low TILs (<30%). In 178 patients treated with neoadjuvant chemotherapy, pathologic complete response (pCR) was higher in those with HRD vs HRR-proficient (HRP) tumours (52.3% vs 36.4%); RAD51 remained independently associated with pCR (p = 0.03). Overall survival (OS) favoured HRD, with 5-year OS of 89.2% vs 82.8% in HRP (p = 0.009), with stronger evidence in triple-negative TILs-low disease (p = 0.005). These findings support RAD51-based HRD assessment as a predictive and prognostic biomarker that may guide treatment decisions in early-stage BC., We acknowledge C. Belli, F. Pedretti, A. Herencia-Ropero, M. Guzmán and O. Rodríguez for technical support. VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, the CERCA program from the Generalitat de Catalunya and patients and families for their support on this research. This study was also supported by the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). This work received funds from Asociación Española contra el cancer [AECC, LABAE16020PORTT], Institutode Salud Carlos III [PI23/00506] and the Catalan Agency AGAUR-FEDER [2021 SGR 01510 to V.S and 2022 SGR 01112 to J.B), AL-G and C.C. were supported by AECC [INVES20095LLOP, AIOC15152806CRUZ].